A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

November 18, 2024 updated by: Astellas Pharma Inc

A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The phase 1 dose escalation portion will establish the maximum tolerated dose (MTD) in patients with advanced solid tumors. Once the recommended phase 2 dose (RP2D) is established for both schedules, the phase 2 study will begin. Patients with relapsed/recurrent epithelial ovarian cancer will be randomized 1:1:1 to 3 treatment groups.

Study Type

Interventional

Enrollment (Actual)

152

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New South Wales
      • WestMead, New South Wales, Australia, 2145
        • Westmead Hospital
    • Queensland
      • South Brisbane, Queensland, Australia, 4101
        • Mater Adult Hospital
    • South Australia
      • North Terrace, South Australia, Australia, 5000
        • Royal Adelaide Hospital
    • Tasmania
      • Launceston, Tasmania, Australia, 7250
        • Launceston General Hospital
    • Victoria
      • Frankston, Victoria, Australia, 3199
        • Frankston Hospital
      • Wodonga, Victoria, Australia, 3690
        • Border Medical Oncology
    • Western Australia
      • Bunbury, Western Australia, Australia, 6230
        • St. John of God Hospital, Bunbury
      • Perth, Western Australia, Australia, 6009
        • Sir Charles Gairdner Hospital
      • Subiaco, Western Australia, Australia, 6008
        • St. John of Gog Hospital, Subiaco
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Juravinski Cancer Center
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Hospital
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • McGill University
      • Kralove, Czechia, 50005
        • University Hospital Hradec Kralove
      • Ostrava- Poruba, Czechia, 70852
        • University Hospital Ostrava
      • Prague, Czechia, 212000
        • General University Hospital, Department of Obstetrics and Gynecology
      • Bologna, Italy, 40138
        • Universitaria di Bologna Policlinico
      • Carpi, Italy, 91012
        • Ospedale di Carpi, AUSL di Modena
      • Milan, Italy, 20141
        • Instituto Europeo di Oncologia
      • Roma, Italy, 67100
        • Oncology IDI- IRCSS
      • Lublin, Poland, 20-090
        • III Oddzial Onkologii Ginekologicznej
      • Poznan, Poland, 61 866
        • Oddzial Radioterapii
      • Poznan, Poland, 61-878
        • Klinika Onkologii AM w Poznaniu
      • Cluj Napoca, Romania, 400015
        • Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala
      • Cluj Napoca, Romania, 400015
        • Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia Radiologie
      • Iasi, Romania, 700106
        • Oncology Medical Centre SCM
      • Mures, Romania, 540072
        • Clinical Caunty Hospital Mures
      • Moscow, Russian Federation, 129128
        • Central Clinical Hospital
      • Moscow, Russian Federation, 143423
        • Moscow City Oncology Hospital
      • Obninsk, Russian Federation, 249036
        • State Institution Medical Radiology Scientific Center
      • St. Petersburg, Russian Federation, 198255
        • Sity Clinical Oncology
      • Bellinzona, Switzerland, CH-6500
        • Ospedale San Giovanni
      • London, United Kingdom, SW3 6JJ
        • Royal Marsden Hospital
      • London, United Kingdom, WC1E 6BT
        • University College Hospital
      • Manchester, United Kingdom, M20 4BX
        • The Christie NHS Foundation Trust
      • Northwood, United Kingdom, HA62RN
        • Mount Vernon Cancer Center
      • Oxford, United Kingdom, OX37LI
        • Churchill Hospital
      • Withington, United Kingdom, M20 4BX
        • Christie NHS Foundation Trust
    • Surrey
      • Sutton, Surrey, United Kingdom, SM2 5PT
        • Drug Development Unit Royal Mardsen NHS Foundation Trust
    • Arizona
      • Scottsdale, Arizona, United States, 85259
        • Mayo Clinic
    • California
      • Orange, California, United States, 92868
        • Department of Obstetrics and Gynecology, University of California, Irvine
    • Indiana
      • Lafayette, Indiana, United States, 47906
        • Horizon Oncology Center
    • Louisiana
      • New Orleans, Louisiana, United States, 70121
        • Ochsner Clinic Foundation
    • New Jersey
      • Morristown, New Jersey, United States, 07960
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, United States, 28204
        • Blumenthal Cancer Center - Main
      • Durham, North Carolina, United States, 27710
        • Duke University Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • University of Oklahoma Health Sciences Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically or cytologically confirmed epithelial ovarian carcinoma Patients with fallopian or peritoneal cancer will also be eligible
  • Patients with any solid tumor that may be treated with weekly paclitaxel will be eligible for the phase 1 portion
  • For the phase 2 portion, patients must have elevated CA125 levels evaluable/assessable according to Gynecological Cancer Intergroup (GCIG) criteria (ie, > 70 U/mL) documented by 2 measurements at least 1 week apart
  • Patients must have radiologically confirmed progressive disease by RECIST v1.1 criteria within 6 months prior to randomization. (patients must have measurable disease according to RECIST v1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 -1
  • Predicted life expectancy ≥ 12 weeks
  • Patients may have had prior therapy, providing the following conditions are met:

    • Chemotherapy: Prior chemotherapy must have been completed at least 3 weeks prior to study enrollment (6 weeks for mitomycin C, nitrosoureas or high-dose carboplatin [≥ 600 mg/m²]and 4 weeks for investigational drugs

      1. Patient should have recovered from any drug-related toxicities (with the exception of grade 1 neuropathy and or alopecia)
      2. Phase 1: While there is no limit on the number of prior regimens for patients entered into the phase 1 portion, any prior taxane therapy must have been administered on a 3 week schedule
      3. Phase 2: Patients must have received prior chemotherapy, which must have contained a platinum and a taxanes at some point. Any prior taxanes therapy must have been administered on a 3 week schedule. A maximum of 2 prior chemotherapy regimens are permitted. Patients must be refractory radiologically confirmed by computerized tomography (CT) scan progressive disease (PD) during chemotherapy) or resistant (radiologically confirmed by CT scan PD within six months of completing chemotherapy) to their last platinum-containing chemotherapy regimen
    • Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration/randomization. Radiated lesions cannot be chosen as the target lesions

      a. A minimum of 21 days must have elapsed between the end of radiotherapy and registration/randomization into the study unless the radiation affected less than 25% of bone marrow

    • Surgery: Previous surgery is permitted provided that adequate wound healing has occurred prior to registration/randomization
  • Fasting glucose ≤ 150 mg/dL (8.3 mmol/L)
  • Adequate hematopoietic, hepatic, and renal function defined as follows:

    • Neutrophil count ≥ 1.5 x 10 ^9 /L and platelet count > = 100 x 10^9/L;
    • Bilirubin ≤ 1.5 x Upper Limit of Normal (ULN);
    • AST and/or ALT ≤ 2.5 x ULN or < = 5 x ULN if patient has documented liver metastases; and
    • Serum creatinine ≤ 1.5 x ULN
  • Female patient must be either:

    • Of non childbearing potential:

      1. post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
      2. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)
    • Or, if of childbearing potential:

      1. must have a negative urine pregnancy test at Screening, and
      2. must use two forms of birth control (one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days [or 5 half lives, whichever is longer] after final study drug administration
  • Female patient must not be breastfeeding at Screening or during the study period and for 28 days [or 5 half lives of the study drug whichever is longer] after final study drug administration
  • Female patient must not donate ova starting at Screening and throughout the study period and for 28 days [or 5 half lives of the study drug whichever is longer] after final study drug administration
  • Patients must provide verbal and written informed consent to participate in the study

Exclusion Criteria:

  • Diabetes mellitus currently requiring medication (eg, insulin or oral hypoglycemics)
  • During the phase 2 portion, patients with histology of abdominal adenocarcinoma of unknown origin or a diagnosis of a borderline ovarian tumor
  • Previous or concurrent malignancies (excluding curatively treated basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) unless the patient has been in remission for at least 3 years
  • History of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of cerebrovascular accident (CVA) within 6 months prior to registration/randomization or that is not stable
  • Prior therapy with an insulin-like growth factor (IGF-1R) inhibitor
  • Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing
  • Known or prior hypersensitivity to taxanes in spite of premedication or drugs containing Cremophor
  • Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation,active peptic ulcer or prior surgical procedures or bowel resection affecting absorption
  • Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to registration/randomization) that would impair the ability of the patient to receive protocol treatment
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
  • Pregnancy or breast-feeding
  • Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to registration/randomization
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded. Patients with mean QTcF interval ≥ 450 msec at screening are excluded
  • Use of drugs that have a known risk of causing Torsade de Pointes (TdP) or that that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing are prohibited
  • Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • Participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening or during the course of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase 1 Arm A
Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
Administered intravenously
Administered orally
Experimental: Phase 1 Arm B1
Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
Administered intravenously
Administered orally
Experimental: Phase 1 Arm B2
Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
Administered intravenously
Administered orally
Experimental: Phase 1 Arm B3
Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
Administered intravenously
Administered orally
Experimental: Phase 2 Arm A
Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
Administered intravenously
Administered orally
Experimental: Phase 2 Arm B
Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
Administered intravenously
Administered orally
Experimental: Phase 2 Arm C
Paclitaxel on Days 1, 8, and 15
Administered intravenously
Experimental: Phase 2 Arm C Roll-over
Continuous OSI-906 BID from Day 1 onwards
Administered orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Time Frame: 28 days
Primary outcome measure for Phase 1 portion
28 days
Progression Free Survival (PFS)
Time Frame: 36 months
Primary outcome measure for the Phase 2 portion; The time from the date of randomization until date of radiographic disease progression per RECIST v1.1 or until death due to any cause
36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR)
Time Frame: 36 months
The proportion of patients with a confirmed response of Complete Response (CR) or Partial Response (PR) per RECEIST v1.1
36 months
Cancer Antigen 125 (CA125) Response Rate
Time Frame: 36 months
Response Rate is defined as at least 50% reduction in serum CA-125 levels from pretreatment levels; Response rate is the proportion of patients with a CA-125 response among evaluable patients
36 months
Duration of Response (DOR)
Time Frame: 36 months
The time from the date of the first documented radiographic response (CR/PR) to first documented radiographic progression or death due to underlying cancer
36 months
Duration of CA-125 Response (CA-125 DOR)
Time Frame: 36 months
The time from the date of the first documented CA-125 response to the date of CA-125 progression
36 months
Overall Survival (OS)
Time Frame: 36 months
The time from the date of randomization until the documented date of death
36 months
Safety assessed via physician exam, vital signs, clinical laboratory tests, electrocardiograms (ECG), and adverse events
Time Frame: 36 months
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Principal Investigator - Czech Republic, General Faculty Hospital, Charles University
  • Principal Investigator: Principal Investigator - Italy, Instituto Europeo de Oncologia
  • Study Director: Medical Director, Astellas Pharma Global Development

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 5, 2009

Primary Completion (Actual)

August 1, 2014

Study Completion (Actual)

August 25, 2014

Study Registration Dates

First Submitted

April 6, 2009

First Submitted That Met QC Criteria

April 24, 2009

First Posted (Estimated)

April 28, 2009

Study Record Updates

Last Update Posted (Actual)

November 20, 2024

Last Update Submitted That Met QC Criteria

November 18, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

IPD Sharing Time Frame

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

IPD Sharing Access Criteria

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe